Feasibility of Placing Bravo PH Capsule in Proximal Esophagus (bravo)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00378898|
Recruitment Status : Completed
First Posted : September 21, 2006
Results First Posted : April 4, 2017
Last Update Posted : April 4, 2017
Assessing the feasibility and patient tolerance to placement of Bravo PH capsule in proximal esophagus.
There will be no difference in patient-perception of a proximally-placed Bravo esophageal pH monitor compared with a distal monitor.
|Condition or disease||Intervention/treatment||Phase|
|Gastroesophageal Reflux Disease||Device: BRAVO capsule Procedure: Fluoroscopy Other: sham BRAVO capsule placement||Not Applicable|
24-hour pH monitoring is often considered the "gold standard" in the diagnosis of GERD and is increasingly utilized in patients with extra-esophageal symptoms (1). However, the clinical utility of pH monitoring in this patient population remains controversial. An important limitation of traditional pH catheters is their suboptimal sensitivity especially in patients with extraesophageal GERD. Vaezi et al. tested reproducibility and reliability of the proximal and distal esophageal pH probe in 32 patients (2). Among these patients,11 were controls, 10 had distal reflux, and 11 had both proximal and distal reflux. In this group of patients the sensitivity of distal and proximal pH probes were 70% and 55%, respectively. Additionally, a more recent study by Shaker et al. showed the number and duration of hypopharyngeal reflux events to be similar between the control subjects and patients with reflux laryngitis and vasomotor rhinitis (3).
Poor sensitivity of catheter based pH monitoring in detecting acid reflux may be due to day to day variability of test, its less than adequate reliability as well as possible intermittent nature of the reflux events (not recorded in only a 24-hour period) (4). Additionally, since the traditional ambulatory device is commonly placed transnasally through the oropharynx into the esophagus, patients often complain of throat and nose discomfort and usually restrict their daily activity. This potentially leads to false negative findings and reduced test sensitivity. Furthermore, incorrect results may be collected if the pH electrode slips away from the initial manometrically determined placement site. In light of these limitations, a new wireless (catheter free) pH monitoring device was developed to improve patient comfort and increase test sensitivity. The Bravo pH monitoring system (Medtronic Inc, Minneapolis, MN) uses a radiotelemetric capsule temporarily attached to the esophageal mucosa which transmits pH data to a receiver carried on patient's belt.
Although well studied in the distal esophagus, there are currently no studies in adults assessing the feasibility and patient tolerance to placement of this device more proximally. Such a placement may increase the sensitivity of the test and add to our ability to study potential predictors of treatment response in patients with extraesophageal GERD.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||39 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||DUAL BRAVO PH MONITORING: A Feasibility Trial|
|Study Start Date :||September 2006|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||July 2009|
Active Comparator: EGD with proximal BRAVO capsule
Subjects have a second BRAVO capsule placed 10cm proximal to prior BRAVO capsule placement. Fluoroscopy is used to confirm detachment of the monitor 7 days after investigational deployment.
Device: BRAVO capsule
one time "xray" to determine evacuation of bravo
Other Name: one time "xray" to determine evacuation of bravo
Sham Comparator: EGD with sham BRAVO capsule placement
Subjects have a EGD with BRAVO delivery introducer positioned 10cm proximal to prior BRAVO capsule placement with no BRAVO placed.
Other: sham BRAVO capsule placement
- Patients Requiring Endoscopic Removal of BRAVO Because of Reported Discomfort [ Time Frame: 48 hours ]
- Subjects Reporting Chest Pain [ Time Frame: 48 hours ]Edmonton Symptom Assessment is used to measure the presence and change in symptoms.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00378898
|United States, Tennessee|
|The Vanderbilt Clinic/ Endoscopy Lab|
|Nashville, Tennessee, United States, 37232-5280|
|Principal Investigator:||Michael F Vaezi, MD, PhD||Vanderbilt University|